MétaCan
Menu
Back to cohort
Record W1875134139 · doi:10.1093/schbul/sbv125

A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes

2015· article· en· W1875134139 on OpenAlexaff
Delbert G. Robinson, Juan A. Gallego, Majnu John, Georgios Petrides, Youssef Hassoun, Jianping Zhang, Leonardo V. Lopez, Raphael J. Braga, Serge Sevy, Jean Addington, Charles H. Kellner, Mauricio Tohen, Melissa Naraine, Natasha Bennett, Jessica Greenberg, Todd Lencz, Christoph U. Correll, John M. Kane, Anil K. Malhotra

Bibliographic record

VenueSchizophrenia Bulletin · 2015
Typearticle
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsUniversity of Calgary
FundersJanssen PharmaceuticalsSt. Jude MedicalGenentechNational Institutes of HealthH. Lundbeck A/SGedeon RichterUniversity of CambridgeGlaxoSmithKlineFORUM PharmaceuticalsLes Laboratories Pierre FabreSunovionNovo NordiskTeva Pharmaceutical IndustriesBristol-Myers SquibbEli Lilly and CompanyAstraZenecaNational Alliance for Research on Schizophrenia and DepressionAmgenNational Institute of Mental HealthPfizer
KeywordsAripiprazoleRisperidoneAkathisiaSchizophreniform disorderPsychologySchizoaffective disorderBipolar I disorderSchizophrenia (object-oriented programming)PsychiatryContext (archaeology)AntipsychoticExtrapyramidal symptomsRandomized controlled trialInternal medicinePartial agonistPositive and Negative Syndrome ScaleMedicineMoodBipolar disorderPsychosisMania

Abstract

fetched live from OpenAlex

Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15-40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5-30 mg/d) or risperidone (1-6 mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% vs 56.8%) nor did time to response. Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia. Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Post hoc analyses suggested advantages for aripiprazole on depressed mood. Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole. Otherwise, aripiprazole would be the preferred choice over risperidone in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.042
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.315
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations111
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueSchizophrenia BulletinSame topicSchizophrenia research and treatmentFrench-language works237,207